Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB.

Oncologist. 2010;15(7):699-731. doi: 10.1634/theoncologist.2010-0025. Epub 2010 Jun 28. Review.

2.

Clinical biomarkers in oncology: focus on colorectal cancer.

De Roock W, Biesmans B, De Schutter J, Tejpar S.

Mol Diagn Ther. 2009;13(2):103-14. doi: 10.2165/01250444-200913020-00004. Review.

PMID:
19537845
3.

Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.

Custodio A, Feliu J.

Crit Rev Oncol Hematol. 2013 Jan;85(1):45-81. doi: 10.1016/j.critrevonc.2012.05.001. Epub 2012 May 28. Review.

PMID:
22647972
4.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

5.

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.

J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. doi: 10.1093/jnci/djp280. Epub 2009 Sep 8. Review.

6.

Predictive molecular classifiers in colorectal cancer.

Bohanes P, LaBonte MJ, Winder T, Lenz HJ.

Semin Oncol. 2011 Aug;38(4):576-87. doi: 10.1053/j.seminoncol.2011.05.012. Review.

PMID:
21810517
7.

[Biomarker for colorectal cancer].

Nagasaka T, Mori Y, Umeda Y, Fujiwara T.

Nihon Rinsho. 2012 May;70(5):802-8. Japanese.

PMID:
22620004
8.

Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.

Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A.

J Pathol. 2011 Nov;225(3):336-43. doi: 10.1002/path.2879. Epub 2011 Jun 9.

PMID:
21660972
9.

Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach.

Legolvan MP, Taliano RJ, Resnick MB.

Hum Pathol. 2012 Aug;43(8):1157-68. doi: 10.1016/j.humpath.2012.03.003. Epub 2012 Jun 1. Review.

PMID:
22658275
10.

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.

Montagut C, Iglesias M, Arumi M, Bellosillo B, Gallen M, Martinez-Fernandez A, Martinez-Aviles L, Cañadas I, Dalmases A, Moragon E, Lema L, Serrano S, Rovira A, Rojo F, Bellmunt J, Albanell J.

Br J Cancer. 2010 Mar 30;102(7):1137-44. doi: 10.1038/sj.bjc.6605612. Epub 2010 Mar 16.

11.

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.

Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1045-55. doi: 10.1007/s00280-011-1586-z. Epub 2011 Feb 22.

PMID:
21340604
12.

CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.

Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH.

Arch Pathol Lab Med. 2008 Oct;132(10):1657-65. doi: 10.1043/1543-2165(2008)132[1657:CIMPIC]2.0.CO;2.

PMID:
18834226
13.

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61. doi: 10.1016/S0305-7372(10)70021-9. Review.

PMID:
21129611
14.

Molecular markers in the treatment of metastatic colorectal cancer.

Wilson PM, Labonte MJ, Lenz HJ.

Cancer J. 2010 May-Jun;16(3):262-72. doi: 10.1097/PPO.0b013e3181e07738. Review.

PMID:
20526105
15.
16.

Development of molecular biomarkers in individualized treatment of colorectal cancer.

De Mattos-Arruda L, Dienstmann R, Tabernero J.

Clin Colorectal Cancer. 2011 Dec;10(4):279-89. doi: 10.1016/j.clcc.2011.03.030. Epub 2011 May 12. Review.

PMID:
21729679
17.

Personalizing therapy for colorectal cancer.

Wong A, Ma BB.

Clin Gastroenterol Hepatol. 2014 Jan;12(1):139-44. doi: 10.1016/j.cgh.2013.08.040. Epub 2013 Sep 8. Review.

PMID:
24025538
18.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

19.
20.

Molecular predictors of response to chemotherapy in colorectal cancer.

Dienstmann R, Vilar E, Tabernero J.

Cancer J. 2011 Mar-Apr;17(2):114-26. doi: 10.1097/PPO.0b013e318212f844. Review.

PMID:
21427555
Items per page

Supplemental Content

Write to the Help Desk